A US-based KOL discusses current standards of care in AML, the efficacy of approved therapies, and the effect of mutational status on treatment outcomes. The clinical development of novel treatments is also discussed, alongside the prospects of drugs in the relapsed/refractory setting. 

This interview was conducted on 10 July 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.